Bull case
Lifecore Biomedical is benefiting from a clear turnaround in which CEO Paul Josephs has built a stronger leadership team, reduced expenses, and shifted the company into an execution phase focused on late-stage and commercial site-transfer wins. The pipeline now exceeds 30 active projects, including over a dozen late-stage or commercial transfers, with the late-stage/site-transfer opportunity estimated at more than $100 million annualized unweighted and over $50 million weighted, while the recent seven additions over seven months should materially expand future revenue. Despite leverage of $184 million in debt, nearly $50 million in convertible preferred stock, and only $17.5 million in cash, affirmed guidance for over $10 million in free cash flow in 2026 and a path to over $200 million in revenue by 2029 supports a positive outlook driven by rising utilization from 20% toward approximately 60%.